Press Releases - Ipsen
Ipsen and bioMérieux enter into a broad partnership in personalized medicine
Ipsen nomme Gwenan White en qualité de Vice-Président Exécutif, Communication et Affaires Publiques | Business Wire
Ipsen intègre un nouveau programme à son portefeuille R&D de produits d'oncologie en phase pré-clinique grâce à une collaboration mondiale exclusive avec Accent Therapeutics, ciblant la protéine modificatrice d'ARN METTL3 | Business
News articles listing - Ipsen
PRESS RELEASE Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patie
Ipsen (@IpsenGroup) / Twitter
Press Releases - Ipsen
PRESS RELEASE Ipsen announces new data to be presented at ASCO in line with its continued commitment to Oncology research
AGV Discovery Press Release French - FINAL
Ipsen acquiert Epizyme et étend son portefeuille en Oncologie | Business Wire
Press Releases - Ipsen UK
PRESS RELEASE
PRESS RELEASE
Press Release for the 5th BiOPEN project workshop: 'Societal and Market Challenges for the Sustainable Development of Bio-Based Industries' – IPSEN
PRESS RELEASE Ipsen expects Increlex supply interruption due to supplier manufacturing issues
PRESS RELEASE
ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different tumor types includin
The FDA approves Somatuline® Depot (lanreotide) Injection Extended Dosing Interval as part of Ipsen's Prior Approval Suppleme
Press Releases - Ipsen UK
PRESS RELEASE
News articles listing - Ipsen
Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
Ipsen and Marengo Therapeutics announce strategic partnership to advance two precision immuno-oncology candidates from Marengo S
